Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04675294
Title Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ALX Oncology Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | GBR | ESP | CAN | BEL | AUS


No variant requirements are available.